Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 16 - Net Loss Per Share

Note 16 - Net Loss Per Share

9 Months Ended

Sep. 30, 2023

Notes to Financial Statements

Earnings Per Share [Text Block]

16. Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2023			2022			2023			2022
Numerator:
Net loss applicable to common stockholders, basic and diluted	$	(3,365	)	$	(4,304	)	$	(11,984	)	$	(11,902	)

Denominator:
Weighted-average number of shares, basic and diluted		14,073			13,071			13,672			12,896

Net loss per share, basic and diluted	$	(0.24	)	$	(0.33	)	$	(0.88	)	$	(0.92	)

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	*Three Months Ended*				*Nine Months Ended*
	*September 30,*				*September 30,*
	*2023*		*2022*		*2023*		*2022*
Options to purchase common stock		254		271		254		271
Restricted stock units		1,474		949		1,474		949
Warrants for common stock		1,240		1,240		1,240		1,240
Total common stock equivalents		2,968		2,460		2,968		2,460